Mechanism of Action

Sermorelin corresponds to GHRH(1-29) and, in published research, binds the growth-hormone-releasing hormone receptor (GHRH-R), a class B G-protein-coupled receptor expressed on anterior-pituitary somatotrophs. Receptor engagement research indicates coupling primarily through Gs, activation of adenylyl cyclase and elevation of intracellular cAMP, with additional MAPK signaling described in the literature; these pathways are associated in research models with both the synthesis and the pulsatile secretion of growth hormone (GH).

Research indicates that GHRH-analog signaling is embedded within a regulated feedback network: hypothalamic somatostatin exerts an opposing inhibitory tone at the somatotroph, and downstream GH and hepatic insulin-like growth factor 1 (IGF-1) provide negative feedback that dampens further GH release. Because of this interplay, the GH response to a GHRH analog observed in research is state-dependent, varying with prevailing somatostatin tone and IGF-1 levels rather than producing an unregulated release. No therapeutic or medical-benefit claims are made or implied.

Research Applications

• → Research established that the N-terminal GHRH(1-29) fragment retains essentially the full growth-hormone-releasing activity of the intact 44-residue GHRH molecule, defining the minimal bioactive core studied as sermorelin.
• → In investigational endocrine studies, intravenous administration of the GHRH(1-29) analog elicited a relatively rapid and specific rise in circulating growth hormone, and it has been examined as a provocative probe of pituitary somatotroph capacity.
• → Controlled research in normal male subjects demonstrated that exogenous growth hormone inhibits GHRH-induced GH secretion, illustrating negative feedback within the somatotropic axis relevant to GHRH-analog signaling.
• → Preclinical and mechanistic literature characterizes GHRH-R as a Gs-coupled receptor whose activation raises cAMP and engages MAPK cascades linked to GH synthesis and pulsatile release.
• → Longitudinal investigational studies of once-daily subcutaneous GHRH(1-29) reported changes in growth-hormone dynamics over multi-month observation windows, informing research on the durability of somatotroph responsiveness to GHRH-analog stimulation.

Analytical Validation

Sermorelin Acetate is verified via LC-MS and HPLC analysis. Each lot is tested for identity, purity (≥99% target), and endotoxin levels. Full certificate of analysis is available upon request.